CliffBio
biologic

Afstyla

Antihemophilic Factor (Recombinant), Single Chain

Loss of exclusivityMay 2028projected — 12-year biologic exclusivity estimate
CompanyCSL Behring Lengnau AG

Drug detail

Brand nameAfstyla
Active ingredientAntihemophilic Factor (Recombinant), Single Chain
Strength250IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalMay 2016
Marketing statusRx

More from CSL Behring Lengnau AG

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Afstyla patent cliff — loss of exclusivity May 2028 | CliffBio